For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Placebo | Group B using saline as a placebo. Placebo: Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug | None | None | 0 | 11 | 0 | 11 | View |
| Lidocaine | Group A lidocaine infusion and bolus. Lidocaine: Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW) | None | None | 0 | 11 | 1 | 11 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| First degree heart block | SYSTEMATIC_ASSESSMENT | Cardiac disorders | MedDRA (10.0) | View |